




RealRate

PHARMACEUTICAL 2018

Sonnet BioTherapeutics Holdings Inc.
Rank 208 of 342





RealRate

PHARMACEUTICAL 2018

Sonnet BioTherapeutics Holdings Inc. Rank 208 of 342



The relative strengths and weaknesses of Sonnet BioTherapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet BioTherapeutics Holdings Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 122% points. The greatest weakness of Sonnet BioTherapeutics Holdings Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is 52%, being 6.8% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	1,800
Cost of Goods Sold	0
Intangible Assets	18,545
Liabilities, Current	14,906
Liabilities, Non-Current	0
Other Assets	2,672
Other Compr. Net Income	592
Other Expenses	41,478
Other Liabilities	4,853
Other Net Income	-2,575
Other Revenues	41,433
Property and Equipment	8,549
Research and Development	0
Selling, General and Administrative Expense	4,545

Output Variable	Value in 1000 USD
Assets	31,565
Liabilities	19,759
Expenses	46,024
Revenues	41,433
Stockholders Equity	11,806
Net Income	-7,166
Comprehensive Net Income	-6,870
Economic Capital Ratio	52%